Sakar Healthcare Limited (NSE:SAKAR)
1,073.95
-1.75 (-0.16%)
Nov 12, 2026, 3:29 PM IST
Sakar Healthcare Revenue
Sakar Healthcare had revenue of 874.16M INR in the quarter ending September 30, 2026, with 51.87% growth. This brings the company's total for the last twelve months to 3.03B, up 48.09% year-over-year. In the fiscal year ending March 31, 2026, Sakar Healthcare had annual revenue of 2.53B with 41.89% growth. That makes Sakar Healthcare the 30,897th largest company in the world by revenue and 2,217th in India.
Revenue (ttm)
3.03B
Revenue Growth
+48.09%
P/S Ratio
7.89
Revenue / Employee
6.96M
Employees
435
Market Cap
23.90B
Revenue by Geography
- Export 1.51B 60.1%
- India 1.00B 39.9%
Fiscal year ended Mar 31, 2026 See the full Sakar Healthcare breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.53B | 746.06M | 41.89% |
| Mar 31, 2025 | 1.78B | 239.40M | 15.53% |
| Mar 31, 2024 | 1.54B | 199.75M | 14.89% |
| Mar 31, 2023 | 1.34B | 50.74M | 3.93% |
| Mar 31, 2022 | 1.29B | 338.06M | 35.47% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 19.09B |
| Solara Active Pharma Sciences | 15.35B |
| Windlas Biotech | 9.93B |
| Orchid Pharma | 8.52B |
| RPG Life Sciences | 7.64B |
| Ind-Swift Laboratories | 7.64B |
| Sigachi Industries | 4.91B |
| Beta Drugs | 4.10B |
Sakar Healthcare News
- 6 months ago - Sakar Healthcare reports 42% revenue growth in Q4FY26 - Business Upturn
- 10 months ago - Sakar Healthcare gets EMA approval to manufacture Imatinib for Accord’s European market - Business Upturn
- 1 year ago - Sakar Healthcare shares rise over 2.5% after securing nine new oncology product approvals across global markets - Business Upturn
- 1 year ago - Sakar Healthcare receives nine new marketing authorisations for Oncology products in EU and emerging markets - Business Upturn